A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
SUCCESSOR-1
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
2 other identifiers
interventional
810
28 countries
261
Brief Summary
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2022
Longer than P75 for phase_3
261 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2022
CompletedFirst Posted
Study publicly available on registry
August 29, 2022
CompletedStudy Start
First participant enrolled
September 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 30, 2033
April 30, 2026
April 1, 2026
4.3 years
August 25, 2022
April 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression-free Survival (PFS)
From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)
Secondary Outcomes (15)
Recommended mezigdomide dose
Up to 12 Months
Plasma concentrations of mezigdomide
Up to 134 Days
Overall Survival (OS)
From date of randomization to date of death due to any cause (Up to approximately 5 years)
Overall Response (OR)
Up to approximately 5 years
Complete Response (CR) or better
Up to approximately 5 Years
- +10 more secondary outcomes
Study Arms (2)
MeziVd (mezigdomide, bortezomib and dexamethasone)
EXPERIMENTALPVd (pomalidomide, bortezomib and dexamethasone)
EXPERIMENTALInterventions
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Eligibility Criteria
You may qualify if:
- \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.
- i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.
- ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).
- iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
- Participants received 1 to 3 prior lines of antimyeloma therapy.
- Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.
You may not qualify if:
- \- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:.
- i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded.
- ii) Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded.
- For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
- Participant has had prior treatment with mezigdomide or pomalidomide.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Celgenelead
Study Sites (266)
Local Institution - 0366
Los Alamitos, California, 90720, United States
Local Institution - 0272
San Diego, California, 92123, United States
Local Institution - 0273
West Hollywood, California, 90069, United States
Local Institution - 0381
Aurora, Colorado, 80045, United States
Local Institution - 0380
Farmington, Connecticut, 06030, United States
Local Institution - 0208
New Haven, Connecticut, 06510, United States
Local Institution - 0303
Coral Springs, Florida, 33321, United States
Local Institution - 0403
Fort Myers, Florida, 33901, United States
Local Institution - 0401
St. Petersburg, Florida, 33701, United States
Local Institution - 0402
West Palm Beach, Florida, 33401, United States
Local Institution - 0211
Athens, Georgia, 30607, United States
Local Institution - 0048
Marietta, Georgia, 30060, United States
Local Institution - 0330
Garden City, Kansas, 67846, United States
Local Institution - 0080
Westwood, Kansas, 66205, United States
Local Institution - 0358
Baton Rouge, Louisiana, 70808, United States
Local Institution - 0255
New Orleans, Louisiana, 70112, United States
Local Institution - 0385
Shreveport, Louisiana, 71103, United States
Local Institution - 0357
Baltimore, Maryland, 21215, United States
Local Institution - 0246
Boston, Massachusetts, 02215, United States
Local Institution - 0271
Ann Arbor, Michigan, 48109, United States
Local Institution - 0364
Detroit, Michigan, 48202, United States
Local Institution - 0410
Minneapolis, Minnesota, 55404, United States
Local Institution - 0088
Hattiesburg, Mississippi, 39401, United States
Local Institution - 0242
Jackson, Mississippi, 39213, United States
Local Institution - 0288
East Brunswick, New Jersey, 08816, United States
Local Institution - 0363
Ridgewood, New Jersey, 07450, United States
Local Institution - 0302
Albuquerque, New Mexico, 87131, United States
Local Institution - 0245
Buffalo, New York, 14215, United States
Local Institution - 0257
Lake Success, New York, 11042, United States
Local Institution - 0373
New Hyde Park, New York, 11042, United States
Local Institution - 0371
New York, New York, 10028, United States
Local Institution - 0108
Rochester, New York, 14621, United States
Local Institution - 0374
Shirley, New York, 11967, United States
Local Institution - 0372
The Bronx, New York, 10469, United States
Local Institution - 0274
Williamsville, New York, 14221, United States
Local Institution - 0260
Durham, North Carolina, 27710, United States
Local Institution - 0400
Cincinnati, Ohio, 45242, United States
Local Institution - 0377
Cleveland, Ohio, 44111, United States
Local Institution - 0076
Cleveland, Ohio, 44195, United States
Local Institution - 0376
Mayfield Heights, Ohio, 44124, United States
Local Institution - 0359
Allentown, Pennsylvania, 18103, United States
Local Institution - 0264
York, Pennsylvania, 17403, United States
Local Institution - 0223
Germantown, Tennessee, 38138, United States
Local Institution - 0378
Abilene, Texas, 79606, United States
Local Institution - 0275
Houston, Texas, 77030, United States
Local Institution - 0267
San Antonio, Texas, 78229, United States
Local Institution - 0409
San Antonio, Texas, 78240, United States
Local Institution - 0207
Salt Lake City, Utah, 84106, United States
Local Institution - 0297
Fredericksburg, Virginia, 22408, United States
Local Institution - 0408
Norfolk, Virginia, 23502, United States
Local Institution - 0399
Roanoke, Virginia, 24014, United States
Local Institution - 0268
Seattle, Washington, 98108, United States
Local Institution - 0293
Seattle, Washington, 98109, United States
Local Institution - 0097
Spokane, Washington, 99208, United States
Local Institution - 0411
Vancouver, Washington, 98684, United States
Local Institution - 0220
Madison, Wisconsin, 53792, United States
Local Institution - 0318
Chivilcoy, Buenos Aires, 6620, Argentina
Local Institution - 0213
Buenos Aires, Buenos Aires F.D., 1425, Argentina
Local Institution - 0249
Córdoba, Córdoba Province, 5016, Argentina
Local Institution - 0239
Viedma, R, R8500ACE, Argentina
Local Institution - 0200
Rosario, Santa Fe Province, 2000, Argentina
Local Institution - 0248
S3000epv, Santa Fe Province, 3000, Argentina
Local Institution - 0214
Buenos Aires, CP1280AEB, Argentina
Local Institution - 0055
Liverpool, New South Wales, 2170, Australia
Local Institution - 0004
Waratah, New South Wales, 2298, Australia
Local Institution - 0017
Wollongong, New South Wales, 2500, Australia
Local Institution - 0327
Birtinya, Queensland, 4575, Australia
Local Institution - 0221
Box Hill, Victoria, 3128, Australia
Local Institution - 0003
Melbourne, Victoria, 3004, Australia
Local Institution - 0002
Melbourne, Victoria, 3065, Australia
Local Institution - 0040
Nedlands, Western Australia, 6009, Australia
Klinik Ottakring
Vienna, State of Vienna, 1160, Austria
Universitätsklinikum Krems
Krems, 3500, Austria
LKH Hochsteiermark - Standort Leoben
Leoben, 8700, Austria
Universitätsklinikum St. Pölten
Sankt Pölten, 3100, Austria
Hanusch-Krankenhaus
Vienna, 1140, Austria
Ziekenhuis Oost-Limburg, Campus St.-Jan
Genk, Limburg, 3600, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, 9000, Belgium
AZ Nikolaas
Sint-Niklaas, Oost-Vlaanderen, B-9100, Belgium
ZNA Cadix
Antwerp, 2030, Belgium
Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
Salvador, Estado de Bahia, 40301-155, Brazil
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
Instituto Joinvilense de Hematologia e Oncologia
Joinville, Santa Catarina, 89202-050, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, 17210-080, Brazil
Americas Centro de Oncologia Integrado
Rio de Janeiro, 22793080, Brazil
Clínica Médica São Germano S/S Ltda
São Paulo, 04537-080, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, 05652-900, Brazil
Local Institution - 0225
Greenfield Park, Quebec, J4V 2H1, Canada
Local Institution - 0174
Montreal, Quebec, H4J 1C5, Canada
Local Institution - 0222
Québec, Quebec, G1J 1Z4, Canada
Local Institution - 0329
Santiago, Santiago Metropolitan, 7580206, Chile
Local Institution - 0387
Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0332
Viña del Mar, Valparaiso, 0, Chile
Local Institution - 0062
Beijing, Beijing Municipality, 100043, China
Local Institution - 0165
Beijing, Beijing Municipality, 100043, China
Local Institution - 0141
Beijing, Beijing Municipality, 100091, China
Local Institution - 0144
Chongqing, Chongqing Municipality, 400016, China
Local Institution - 0237
Xiamen, Fujian, 361003, China
Local Institution - 0117
Guangzhou, Guangdong, 450008, China
Local Institution - 0177
Guangzhou, Guangdong, 510060, China
Local Institution - 0168
Guangzhou, Guangdong, 510080, China
Local Institution - 0238
Shenzhen, Guangdong, 518039, China
Local Institution - 0412
Liuzhou, Guangxi, 0, China
Local Institution - 0240
Nanning, Guangxi, 530007, China
Local Institution - 0254
Shijiazhuang, Hebei, 50000, China
Local Institution - 0395
Luoyang, Henan, 471003, China
Local Institution - 0113
Zhengzhou, Henan, 450003, China
Local Institution - 0142
Wuhan, Hubei, 430022, China
Local Institution - 0155
Changsha, Hunan, 410008, China
Local Institution - 0147
Changsha, Hunan, 410013, China
Local Institution - 0111
Nanjing, Jiangsu, 210000, China
Local Institution - 0139
Wuxi, Jiangsu, 214023, China
Local Institution - 0287
Shenyang, Liaoning, 110004, China
Local Institution - 0148
Xi'an, Shaanxi, 710004, China
Local Institution - 0110
Xi'an, Shaanxi, 710126, China
Local Institution - 0169
Qingdao, Shandong, 266000, China
Local Institution - 0114
Shanghai, Shanghai Municipality, 200030, China
Local Institution - 0350
Shanghai, Shanghai Municipality, 200434, China
Local Institution - 0164
Taiyuan, Shanxi, 030001, China
Local Institution - 0356
Deyang, Sichuan, 618000, China
Local Institution - 0119
Tianjin, Tianjin Municipality, 300060, China
Local Institution - 0353
Ürümqi, Xinjiang, 830001, China
Local Institution - 0202
Kunming, Yunnan, 650032, China
Local Institution - 0151
Hangzhou, Zhejiang, 310003, China
Local Institution - 0348
Linhai, Zhejiang, 317000, China
Local Institution - 0112
Ningbo, Zhejiang, 315010, China
Local Institution - 0149
Wenzhou, Zhejiang, 32500, China
Local Institution - 0150
Beijing, 100034, China
Local Institution - 0176
Taiyuan, 030032, China
Local Institution - 0037
Brno, Brno-město, 625 00, Czechia
Local Institution - 0383
Prague, Praha 10, 100 34, Czechia
Local Institution - 0039
Prague, 12808, Czechia
Local Institution - 0256
Kuopio, Northern Savonia, 70210, Finland
Local Institution - 0072
Helsinki, 00029, Finland
Institut de cancérologie Strasbourg Europe (ICANS)
Strasbourg, Alsace, 67033, France
CHU Bordeaux Haut-Leveque
Pessac, Aquitaine, 33600, France
Centre Leon Berard
Lyon Cedex08, Auvergne-Rhône-Alpes, 69373, France
Hopital Claude Huriez - CHU de Lille
Lille, Nord, 59000, France
Centre Hospitalier Universitaire Estaing
Clermont-Ferrand, 63100, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
Limoges, 87042, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
Nantes, 44093, France
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire Carémeau
Nîmes, 30029, France
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau
Tours, 37032, France
Hôpital Saint Antoine
Paris, Île-de-France Region, 75571, France
TUM Klinikum
München, Bavaria, 81675, Germany
Klinikum Traunstein
Traunstein, Bavaria, 83278, Germany
Medizinisches Versorgungszentrum
Weiden, Bavaria, 92367, Germany
Universitätsklinikum Marburg
Marburg, Hesse, 35033, Germany
Praxis Onkologie am Raschplatz
Hanover, Lower Saxony, 30161, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, 53127, Germany
Marien Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, 40479, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Schleswig-Holstein, 24105, Germany
Local Institution - 0396
Erfurt, Thuringia, 99085, Germany
Universitätsklinikum Aachen
Aachen, 52074, Germany
Sozialstiftung Bamberg
Bamberg, 96049, Germany
Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf
Dresden, 01307, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20251, Germany
Asklepios Altona
Hamburg, 22763, Germany
Universitaetsklinikum Tuebingen
Tübingen, 72076, Germany
Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher
Würzburg, 97080, Germany
Evangelismos General Hospital of Athens
Athens, Attikí, 106 76, Greece
Alexandra General Hospital of Athens
Athens, Attikí, 115 28, Greece
G. Papanikolaou General Hospital
Thessaloniki, Thessaloníki, 570 10, Greece
HCG Aastha Cancer Centre
Ahmedabad, Gujarat, 380060, India
Marengo Asia Hospitals Gurugram
Gurugram, Haryana, 122011, India
KLES Dr. Prabhakar Kore Hospital & M.R.C
Belagavi, Karnataka, 590010, India
Mumbai Oncocare Centre - Nanachowk
Mumbai, Maharashtra, 400036, India
Meenakshi Mission Hospital and Research Centre
Madurai, Tamil Nadu, 625107, India
Tata Memorial Centre - Homi Bhabha Cancer Hospital
Varanasi, Uttar Pradesh, 221002, India
Christian Medical College & Hospital
Ludhiana, 141008, India
Jawaharlal Institute Of Postgraduate Medical Education And Research
Puducherry, 605006, India
Local Institution - 0121
Galway, Connacht, H91 YR71, Ireland
Local Institution - 0122
Cork, T12 E8YV, Ireland
Local Institution - 0120
Dublin, D08 E9P6, Ireland
Local Institution - 0251
Limerick, V94 F858, Ireland
Meir Medical Center
Kfar Saba, Central District, 4428164, Israel
Sheba Medical Center
Ramat Gan, Central District, 5262100, Israel
Hadassah Medical Center - Do Not Use - Duplicate Facility
Jerusalem, Jerusalem, 91220, Israel
Rambam Health Care Campus
Haifa, Northern District, 3109601, Israel
Sourasky Medical Center
Tel Aviv, Tall Abīb, 6423906, Israel
Rabin Medical Center
Peatch Tikva, 49100, Israel
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, Emilia-Romagna, 47014, Italy
Azienda Ospedaliera Sant'Andrea
Rome, Roma, 00189, Italy
Policlinico "G. Rodolico"
Catania, Sicily, 95123, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, 40138, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100, Italy
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
Japan Community Healthcare Organization Kyushu Hospital
Kitakyushu-shi, Fukuoka, 806-8501, Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
Mito Medical Center
Higashiibaraki, Ibaraki, 3113117, Japan
Iwate Medical University Hospital
Shiwa-gun Yahaba-cho, Iwate, 028-3695, Japan
Shonan Kamakura General Hospital
Kamakura, Kanagawa, 247-8533, Japan
Saitama Medical University Hospital
Iruma, Saitama, 350-0495, Japan
Dokkyo Medical University Saitama Medical Center
Koshigaya, Saitama, 343-0845, Japan
Shizuoka Cancer Center
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan
Nihon University Itabashi Hospital
Itabashiku, Tokyo, 173-8610, Japan
Chiba University Hospital
Chiba, 260-8677, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, 810-8563, Japan
Japanese Red Cross Fukuoka Hospital
Fukuoka, 815-8555, Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Hiroshima, 730-0052, Japan
Kumamoto University
Kumamoto, 860-8556, Japan
The Japanese Red Cross Nagasaki Genbaku Hospital
Nagasaki, 852-8104, Japan
The Jikei University Hospital
Tokyo, 105-8461, Japan
Japanese Red Cross Medical Center
Tokyo, 150-8935, Japan
Local Institution - 0335
Tauranga, Bay of Plenty, 3112, New Zealand
Local Institution - 0340
Dunedin, Otago, 9016, New Zealand
Local Institution - 0369
Auckland, 1023, New Zealand
Local Institution - 0334
Auckland, 2025, New Zealand
Local Institution - 0346
Skórzewo, Greater Poland Voivodeship, 60-185, Poland
Local Institution - 0224
Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Local Institution - 0325
Krakow, Lesser Poland Voivodeship, 30-727, Poland
Local Institution - 0250
Warsaw, Masovian Voivodeship, 02-776, Poland
Local Institution - 0292
Słupsk, Pomeranian Voivodeship, 76-200, Poland
Local Institution - 0185
Katowice, 40-519, Poland
Hospital de Braga
Braga, 4710-243, Portugal
Champalimaud Foundation
Lisbon, 1400-038, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
Porto, 4200-072, Portugal
Local Institution - 0355
San Juan, 00909, Puerto Rico
Fundeni Clinical Institute
Bucharest, 022328, Romania
Institutul Oncologic Cluj
Cluj-Napoca, 400124, Romania
Institutul Regional de Oncologie Iasi
Iași, 700483, Romania
Netcare Pretoria East Hospital
Centurion, GP, 0044, South Africa
Groote Schuur Hospital
Cape Town, Western Cape, 7925, South Africa
Haemalife
Kuilsriver, Western Cape, 7580, South Africa
Constantiaberg Haematology
Plumstead, Western Cape, 7800, South Africa
Local Institution - 0106
Busan, Busan, 49241, South Korea
Pusan National University Hospital
Busan, Busan, 49241, South Korea
Local Institution - 0102
Seongnam, Gyeonggido, 13620, South Korea
Seoul National University Bundang Hospital
Seongnam, Gyeonggido, 13620, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeonranamdo, 58128, South Korea
Local Institution - 0103
Hwasun, Jeonranamdo, 58128, South Korea
Local Institution - 0101
Seoul, Seoul Teugbyeolsi, 03080, South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080, South Korea
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, 06351, South Korea
Local Institution - 0104
Seoul, Seoul Teugbyeolsi, 06591, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, Seoul Teugbyeolsi, 06591, South Korea
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
Local Institution - 0105
Seoul, Seoul-teukbyeolsi, 05505, South Korea
Local Institution - 0100
Seoul, 03722, South Korea
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
Local Institution
Seoul, 138-736, South Korea
Local Institution - 0183
Palma, Balearic Islands, 07120, Spain
Hospital Universitari Son Espases
Palma, Balears [Baleares], 07120, Spain
Hospital Clínic de Barcelona
Barcelona, Catalunya [Cataluña], 08036, Spain
Local Institution - 0073
Barcelona, Catalunya [Cataluña], 08036, Spain
Hospital General Universitario Morales Meseguer
Murcia, Murcia, Región de, 30008, Spain
Hospital Costa del Sol
Marbella, Málaga, 29603, Spain
Local Institution - 0182
Marbella, Málaga, 29603, Spain
Hospital San Pedro de Alcantara
Cáceres, 10003, Spain
Complejo Asistencial Universitario de León - Hospital de León
León, 24071, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Local Institution - 0232
Ankara, 06620, Turkey (Türkiye)
Local Institution - 0339
Ankara, 06680, Turkey (Türkiye)
Local Institution - 0228
Istanbul, 34093, Turkey (Türkiye)
Local Institution - 0229
Izmir, 35100, Turkey (Türkiye)
Local Institution - 0226
Kayseri, 0, Turkey (Türkiye)
Local Institution - 0227
Samsun, 55139, Turkey (Türkiye)
Addenbrooke's Hospital
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
The Royal Cornwall Hospital
Truro, England, TR1 3LJ, United Kingdom
Lanarkshire NHS Trust - Monklands Hospital
Airdrie, Great Britain, ML6 OJS, United Kingdom
King's College Hospital
London, Greater London, SE5 9RS, United Kingdom
Leicester Royal Infirmary
Leicester, Leicestershire, LE1 5WW, United Kingdom
Hammersmith Hospital
London, London, City of, W12 0HS, United Kingdom
Barnet Hospital
Barnet, EN5 3DJ, United Kingdom
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, ST4 6QG, United Kingdom
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2022
First Posted
August 29, 2022
Study Start
September 20, 2022
Primary Completion (Estimated)
January 10, 2027
Study Completion (Estimated)
November 30, 2033
Last Updated
April 30, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html